February 21, 2019 – Aging in Motion’s Science Advisory Board Chair, Jack Guralnik, M.D., Ph.D., MPH, received a Lifetime Achievement Award during a ceremony at the International Conference for Frailty and Sarcopenia Research (ICFSR) in Miami Beach, Florida.
The ICFSR Lifetime Achievement Award recognizes researchers that have greatly... Read more »
On April 6, the U.S. Food and Drug Administration (FDA) held its public meeting on Patient-Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on “symptoms and the daily impacts of their condition, current approaches to treatment, and decision factors taken into account when... Read more »
On December 1, the Aging in Motion (AIM) Coalition hosted its second annual meeting in Bethesda, Md., to discuss developments and advances in clinical research and treatment of sarcopenia. The meeting’s theme was “Advancing Therapeutic Development for Sarcopenia: Efforts to Improve Clinical Detection and Endpoint Measures,” which offered updates for stakeholders... Read more »
AIM Executive Director Cynthia Bens was invited by the U.S. Food and Drug Administration (FDA) to speak on two panels at an August 15 public meeting focused on the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA). A few weeks ago, the FDA released its Read more »